Carl Atkinson to Treatment Outcome
This is a "connection" page, showing publications Carl Atkinson has written about Treatment Outcome.
Connection Strength
0.045
-
The Highly Sensitized Recipient: Pretransplant and Posttransplant Considerations. Clin Chest Med. 2023 03; 44(1):85-93.
Score: 0.023
-
A new treatment for neurogenic inflammation caused by EV71 with CR2-targeted complement inhibitor. Virol J. 2012 Nov 23; 9:285.
Score: 0.011
-
A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer. Blood. 2012 Jun 21; 119(25):6043-51.
Score: 0.011